Technical Data
T5050-10B
Thrombopoietin, Recombinant, Human (TPO, Mpl-ligand, MGDF)
2ug
10ug
Molecular Biology Storage: -20CShipping: Blue Ice
Thrombopoietin (Tpo), the ligand for the receptor encoded by the c-Mpl proto-oncogene, is a key regulator of megakaryocytopoiesis and thrombopoiesis in vitro and in vivo. The cDNAs for Tpo have recently been cloned from canine, murine and human sources. The proteins from these three species are highly conserved, exhibiting from 69-75% sequence identity at the amino acid level. Human Tpo cDNA encodes a 353 amino acid residue protein with a 21 amino acid residue signal peptide that is cleaved to yield the 332 amino acid residue mature protein. Two distinct domains, separated by a pair of arginine residues that may be a proteolytic cleavage site, have been identified in Tpo: the amino terminal region exhibiting sequence homology to erythropoietin and the carboxy terminal region containing multiple potential N-linked glycosylation sites. Recombinant Tpo has now been shown to stimulate the maturation, as well as the proliferation, of megakaryocytes and may have important therapeutic applications for the treatment of various clinical conditions associated with thrombocytopenia. Recombinant Human TPO is approximately 80kD, consisting of a 332 amino acid residue with a predicted molecular mass of approximately 35kD. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 8010kD in SDS-PAGE.

AA Sequence:
SPAPPACDLR VLSKLLRDSH VLHSRLSQCP EVHPLPTPVL LPAVDFSLGE WKTQMEETKA QDILGAVTLL LEGVMAARGQ LGPTCLSSLL GQLSGQVRLL LGALQSLLGT QLPPQGRTTA HKDPNAIFLS FQHLLRGKVR FLMLVGGSTL CVRRAPPTTA VPSRTSLVLT LNELPNRTSG LLETNFTASA RTTGSGLLKW QQGFRAKIPG LLNQTSRSLD QIPGYLNRIH ELLNGTRGLF PGPSRRTLGA PDISSGTSDT GSLPPNLQPG YSPSPTHPPT GQYTLFPLPP TLPTPVVQLH PLLPDPSAPT PTPTSPLLNT SYTHSQNLSQ EG

Biological Activity:
rHuTPO is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of MO7e cells is 1-3 ng/ml, corresponding to a Specific Activity of 1 x 106 IU/mg.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months. Reconstitute with ddH2O and carrier protein (0.1% HSA or BSA). Aliquot and store at -20C. Reconstituted product is stable for 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~80kD
Source: CHO cells
Purity: ~ 97% as determined by Analysis by RP-HPLC, Anion-exchange FPLC or Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder in 20mM sodium citrate buffer, pH 6.9. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to 100ug/ml, which can then be further diluted to other aqueous solutions.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Nucleic Acids Res 2006 May 5;34(8):2355-63 2. Circulation 2006 May 9;113(18):2211-20 3. Haematologica 2006 Apr;91(4):445-51 4. Curr HIV Res 2006 Jan;4(1):107-16 5. Exp Hematol 2006 Jan;34(1):87-96 6. Exp Hematol 2006 Jan;34(1):82-6

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.